Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
AstraZeneca
Medtronic
Dow
Moodys

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Sitaxentan

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Sitaxentan: Sponsors, patents, clinical trial progress

Sitaxentan is an investigational drug.

There have been 10 clinical trials for Sitaxentan. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2010.

The most common disease conditions in clinical trials are Familial Primary Pulmonary Hypertension, Hypertension, and Hypertension, Pulmonary. The leading clinical trial sponsors are Pfizer, Encysive Pharmaceuticals, and Institut National de la Santé Et de la Recherche Médicale, France.

There are twenty-one US patents protecting this investigational drug and seven hundred and twenty-one international patents.

Recent Clinical Trials for Sitaxentan
TitleSponsorPhase
Drug Interaction Between Ritonavir And SitaxsentanPfizerPhase 1
Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension PatientsPfizerPhase 3
A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple DosesPfizerPhase 1

See all Sitaxentan clinical trials

Clinical Trial Summary for Sitaxentan

Top disease conditions for Sitaxentan
Top clinical trial sponsors for Sitaxentan

See all Sitaxentan clinical trials

US Patents for Sitaxentan

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Sitaxentan   Start Trial Method for preventing or treating erectile dysfunction by administering an endothelin antagonist Bristol-Myers Squibb Company (Princeton, NJ)   Start Trial
Sitaxentan   Start Trial Method for preventing or treating pain by administering an endothelin antagonist Bristol-Myers Squibb Co. (Princeton, NJ)   Start Trial
Sitaxentan   Start Trial Sulfonamides and derivatives thereof that modulate the activity of endothelin Encysive Pharmaceuticals Inc. (Bellaire, TX)   Start Trial
Sitaxentan   Start Trial Sulfamidothienopyrimidines Merck Patent GmbH (Darmstadt, DE)   Start Trial
Sitaxentan   Start Trial Amide derivatives as inhibitors of the enzymatic activity of renin Novartis AG (Basel, CH)   Start Trial
Sitaxentan   Start Trial Pyrimidine derivatives Merck Patent GmbH (Darmstadt, DE)   Start Trial
Sitaxentan   Start Trial Respiratory drug condensation aerosols and methods of making and using them Alexza Pharmaceuticals, Inc. (Mountain View, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Sitaxentan

Drugname Country Document Number Estimated Expiration Related US Patent
Sitaxentan Argentina 247246 2011-10-22   Start Trial
Sitaxentan Austria 174592 2011-10-22   Start Trial
Sitaxentan Austria 198146 2011-10-22   Start Trial
Sitaxentan Austria 225635 2011-10-22   Start Trial
Sitaxentan Austria 243203 2011-10-22   Start Trial
Sitaxentan Austria 270669 2011-10-22   Start Trial
Sitaxentan Australia 2711192 2011-10-22   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
AstraZeneca
McKinsey
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.